RU2019103647A3 - - Google Patents

Download PDF

Info

Publication number
RU2019103647A3
RU2019103647A3 RU2019103647A RU2019103647A RU2019103647A3 RU 2019103647 A3 RU2019103647 A3 RU 2019103647A3 RU 2019103647 A RU2019103647 A RU 2019103647A RU 2019103647 A RU2019103647 A RU 2019103647A RU 2019103647 A3 RU2019103647 A3 RU 2019103647A3
Authority
RU
Russia
Application number
RU2019103647A
Other languages
Russian (ru)
Other versions
RU2019103647A (ru
RU2750670C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019103647A publication Critical patent/RU2019103647A/ru
Publication of RU2019103647A3 publication Critical patent/RU2019103647A3/ru
Application granted granted Critical
Publication of RU2750670C2 publication Critical patent/RU2750670C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2019103647A 2016-07-29 2017-07-28 Композиция с задержанным высвобождением, содержащая микронизированный толкапон RU2750670C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382372.7 2016-07-29
EP16382372.7A EP3275433A1 (en) 2016-07-29 2016-07-29 Sustained release composition comprising micronized tolcapone
PCT/EP2017/069168 WO2018019997A1 (en) 2016-07-29 2017-07-28 Sustained release composition comprising micronized tolcapone

Publications (3)

Publication Number Publication Date
RU2019103647A RU2019103647A (ru) 2020-08-28
RU2019103647A3 true RU2019103647A3 (enExample) 2020-10-12
RU2750670C2 RU2750670C2 (ru) 2021-06-30

Family

ID=56571284

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019103647A RU2750670C2 (ru) 2016-07-29 2017-07-28 Композиция с задержанным высвобождением, содержащая микронизированный толкапон

Country Status (12)

Country Link
US (2) US11883538B2 (enExample)
EP (2) EP3275433A1 (enExample)
JP (1) JP7047236B2 (enExample)
KR (1) KR102484678B1 (enExample)
CN (1) CN109789100A (enExample)
AU (1) AU2017303333B2 (enExample)
DK (1) DK3490535T3 (enExample)
ES (1) ES2891355T3 (enExample)
MX (1) MX391116B (enExample)
PT (1) PT3490535T (enExample)
RU (1) RU2750670C2 (enExample)
WO (1) WO2018019997A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024081554A2 (en) * 2022-10-10 2024-04-18 Corino Therapeutics, Inc. Modified release tolcapone formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
DE69733752T2 (de) 1996-05-20 2006-06-01 G.D. Searle Llc, Chicago Arzneimittel enthaltend oxaprozin-natriumsalz,-kaliumsalz, oder-tris(hydroxymethyl)aminomethansalz
WO1999052504A1 (en) * 1998-04-09 1999-10-21 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
US6599530B2 (en) * 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
CA2510320C (en) * 2002-12-20 2012-10-09 St. James Associates Llc/Faber Research Series Coated particles for sustained-release pharmaceutical administration
EP2335696A1 (en) * 2005-06-08 2011-06-22 Orion Corporation An entacapone-containing oral dosage form
WO2008087882A1 (ja) 2007-01-15 2008-07-24 Kissei Pharmaceutical Co., Ltd. 胃内滞留型レボドパ徐放性製剤
SI2640358T1 (en) * 2010-11-15 2018-05-31 Neuroderm Ltd. Continuous administration of L-dopa, dopamine decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and compositions thereof
MX355309B (es) 2011-03-14 2018-04-16 Boehringer Ingelheim Int Inhibidores de benzodioxano de la produccion de leucotrieno.
WO2013060668A1 (en) * 2011-10-24 2013-05-02 Som Innovation Biotech, S.L. New therapy for transthyretin-associated amyloidosis
US20130195973A1 (en) * 2012-01-30 2013-08-01 Ranbaxy Laboratories Limited Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof
CN105209029A (zh) * 2013-03-13 2015-12-30 纽罗德姆有限公司 帕金森病的治疗方法
ES2957768T3 (es) * 2013-11-05 2024-01-25 Synagile Corp Suministro continuo de fármacos a través de la boca
CA3175785A1 (en) * 2014-09-04 2016-03-10 Intrance International Ab Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof

Also Published As

Publication number Publication date
RU2019103647A (ru) 2020-08-28
JP7047236B2 (ja) 2022-04-05
KR102484678B1 (ko) 2023-01-03
US20190167596A1 (en) 2019-06-06
MX391116B (es) 2025-03-21
EP3275433A1 (en) 2018-01-31
EP3490535A1 (en) 2019-06-05
KR20190034563A (ko) 2019-04-02
US11883538B2 (en) 2024-01-30
AU2017303333B2 (en) 2023-03-30
JP2019523305A (ja) 2019-08-22
US20240216282A1 (en) 2024-07-04
EP3490535B1 (en) 2021-07-14
MX2019001190A (es) 2019-09-06
AU2017303333A1 (en) 2019-03-14
PT3490535T (pt) 2021-09-30
CA3032211A1 (en) 2018-02-01
US12220487B2 (en) 2025-02-11
DK3490535T3 (da) 2021-10-04
WO2018019997A1 (en) 2018-02-01
BR112019001826A2 (pt) 2019-05-07
ES2891355T3 (es) 2022-01-27
CN109789100A (zh) 2019-05-21
RU2750670C2 (ru) 2021-06-30

Similar Documents

Publication Publication Date Title
BR112019008300A2 (enExample)
BR112019009210A2 (enExample)
BR202016021516U2 (enExample)
CN303634470S (enExample)
CN303537291S (enExample)
CN303401001S8 (enExample)
CN303535544S (enExample)
CN303535548S (enExample)
CN303535882S (enExample)
CN303536047S (enExample)
CN303536110S (enExample)
CN303536111S (enExample)
CN303536216S (enExample)
CN303536230S (enExample)
CN303536235S (enExample)
CN303536238S (enExample)
CN303536242S (enExample)
CN303536358S (enExample)
CN303536489S (enExample)
CN303536492S (enExample)
CN303536516S (enExample)
CN303536547S (enExample)
CN303536629S (enExample)
CN303536737S (enExample)
CN303536802S (enExample)